We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+10.92%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$355M
AUM Growth
-$16.8M
Cap. Flow
-$17.7M
Cap. Flow %
-4.99%
Top 10 Hldgs %
50.26%
Holding
90
New
4
Increased
16
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$9.25M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$4.36M
3
BHVN icon
Biohaven
BHVN
+$3.33M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.13M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.14M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$16.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$5.82M
3
ACET icon
Adicet Bio
ACET
+$4.74M
4
AERI
Aerie Pharmaceuticals
AERI
+$4.65M
5
ETNB
89bio
ETNB
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
$4.16M 1.17%
616,032
+360,719
+141% +$1.93M
ETNB
27
DELISTED
89bio
ETNB
$4.13M 1.16%
324,173
-330,689
-50% -$2.98M
CSII
28
DELISTED
Cardiovascular Systems, Inc.
CSII
$3.91M 1.1%
286,988
– –
DICE
29
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$3.85M 1.09%
123,500
+45,000
+57% +$1.47M
FSTX
30
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.65M 1.03%
576,881
– –
BCYC
31
Bicycle Therapeutics
BCYC
$280M
$3.62M 1.02%
122,200
– –
MRTX
32
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.33M 0.94%
73,600
+2,000
+3% +$129K
AXGN icon
33
Axogen
AXGN
$2.44B
$3.31M 0.93%
332,103
– –
ATRC icon
34
AtriCure
ATRC
$2.02B
$3.2M 0.9%
72,029
– –
CMPX icon
35
Compass Therapeutics
CMPX
$348M
$3.03M 0.85%
602,051
+413,957
+220% +$1.65M
RCUS icon
36
Arcus Biosciences
RCUS
$3.63B
$2.94M 0.83%
142,217
-36,500
-20% -$1M
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.39B
$2.88M 0.81%
+251,000
New +$3.13M
MDWD icon
38
MediWound
MDWD
$186M
$2.75M 0.78%
204,082
– –
ARAY icon
39
Accuray
ARAY
$33.1M
$2.55M 0.72%
1,222,358
+280,558
+30% +$580K
IPSC icon
40
Century Therapeutics
IPSC
$361M
$2.44M 0.69%
475,367
– –
MRSN
41
DELISTED
Mersana Therapeutics
MRSN
$2.42M 0.68%
16,539
+1,428
+9% +$241K
LKFT
42
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.7B
$2.34M 0.66%
52,675
+10,000
+23% +$421K
AUTL
43
Autolus Therapeutics
AUTL
$532M
$2.23M 0.63%
1,176,150
+680,000
+137% +$1.72M
STIM icon
44
Neuronetics
STIM
$160M
$2.16M 0.61%
313,717
– –
VIGL
45
DELISTED
Vigil Neuroscience
VIGL
$2.11M 0.59%
168,846
-47,549
-22% -$584K
LRMR icon
46
Larimar Therapeutics
LRMR
$445M
$1.95M 0.55%
473,136
-101,860
-18% -$348K
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
$1.92M 0.54%
98,560
+1,000
+1% +$19.5K
KURA icon
48
Kura Oncology
KURA
$848M
$1.8M 0.51%
144,784
-61,545
-30% -$895K
KROS icon
49
Keros Therapeutics
KROS
$200M
$1.58M 0.45%
33,000
-6,000
-15% -$280K
ORIC icon
50
Oric Pharmaceuticals
ORIC
$1.35B
$1.56M 0.44%
264,237
-149,289
-36% -$504K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, DAFNA Capital Management held 90 positions worth $355M, down 4.5% from $372M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management withdrew a net $17.7M in Q4 2022, closing 11 positions and reducing 25 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 82% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in BioCryst Pharmaceuticals worth $2.88M.

  • DAFNA Capital Management's largest Q4 2022 buy was BioCryst Pharmaceuticals: 251,000 shares worth $2.88M.
  • DAFNA Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q4 2022, an estimated $9.25M increase.
  • DAFNA Capital Management's biggest Q4 2022 reduction was Cymabay Therapeutics, cutting an estimated $5.82M.
  • DAFNA Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $16.6M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $355M portfolio in Q4 2022.
  • DAFNA Capital Management opened 4 new positions and closed 11 in Q4 2022.
  • DAFNA Capital Management's portfolio value fell 4.5% quarter-over-quarter to $355M.

Based on DAFNA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.